Cedarburg Hauser has ramped up production capacity at its API plant in Wisconsin, US citing customer demand.
The Grafton-based contract manufacturing organisation (CM) has added a 30 ton process chiller, an additional 200 kilowatt backup generator and an industrial vacuum pump to the plant which it expects to increase capacity by 20-25%.
CEO Tony Laughrey said: "Our customer's demand for Cedarburg Hauser commercial APIs continues to grow; upgrading our facilities are a must as we grow with our customers," he added that "we will continue to upgrade and expand our facilities, ensuring supply for our customers."
Operations director John Flahive was equally positive, adding that: “The upgrades to our manufacturing facility are all about operational efficiency.”
“With these improvements we are able to increase our functional capacity by approximately 20%, allowing us to produce more material in a shorter amount of time for our clients.”
The expansion is the second that Cedarburg has made at the facility in as many years and the second time it has increased industrial chiller capacity.
At the time of the first expansion CEO Tony Laughrey said: “We will continue to invest in our business as we strive to be the premier contract API manufacturer.”
Cedarburg has produced steroids, prostaglandins, vitamin D analogs and compounds that are conjugated to polymers or peptides at the Grafton site for many years.
However, since the previous expansion it has started working with potent and cytotoxic compounds as spokesman Bob Forner told Outsourcing-pharma.com when we spoke with him at the time.
He explained the firm had “filed drug master files (DMFs) with the FDA for a schedule II opioid, fentanyl, two steroids, exemestane and oxandralone, and a prostaglandin, travoprost, among other compounds.”